American Journal of Transplantation· 2012Q1
Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant
- 932citations
- Q1SCImago
- 2012year
Short summary
In 15% of kidney transplant recipients (47/315) without pre-existing antibodies, de novo donor-specific HLA antibodies (dnDSA) developed a median of 4.6 years post-transplant, significantly reducing 10-year graft survival to 57% compared to 96% in those without dnDSA.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Transplantation
TransplantationMedicine